Allergy Asthma and Clinical Immunology, a pioneering open access journal published by BMC, has been at the forefront of immunological research since its inception in 2005. With an ISSN of 1710-1492, this UK-based journal has established a significant presence in the fields of Immunology, Allergy, and Pulmonary and Respiratory Medicine, achieving notable quartile rankings such as Q2 in Immunology and Allergy in 2023. It plays a crucial role in disseminating high-quality research that advances our understanding of allergy and asthma, making substantial contributions to clinical practices and public health. The journal embraces the principles of Open Access, allowing researchers, professionals, and students from around the globe to access its content freely, thus facilitating knowledge sharing and collaboration within the scientific community. As it converges towards 2024, Allergy Asthma and Clinical Immunology continues to attract impactful studies that drive innovation and improve patient care in the face of rapidly evolving challenges in immunological health.

Current Treatment Options in Allergy is an esteemed academic journal published by SpringerNature, focusing on a critical area of health science: the evolving landscape of allergy treatments. With an E-ISSN of 2196-3053, this journal aims to provide a comprehensive platform for researchers and practitioners in the fields of Immunology and Allergy and Medicine. It has garnered recognition in the academic community, reflecting its significant contribution with a Q3 ranking in Immunology and Allergy and a Q3 ranking in Medicine as of 2023. The journal is based in Switzerland and encompasses research spanning from 2014 to 2024, ensuring that the latest findings and treatment options are available to professionals and students alike. With a growing focus on open access, it aims to make critical allergy treatment research widely accessible, thus fostering innovation and collaboration in this vital health sector. As the prevalence of allergies continues to rise globally, Current Treatment Options in Allergy plays a crucial role in disseminating important research and treatment strategies to improve patient outcomes.

Allergy Asthma & Respiratory Disease is a pioneering journal dedicated to advancing research and clinical practice in the fields of allergy, asthma, and related respiratory diseases. Published by the esteemed Korean Academy of Asthma Allergy & Clinical Immunology, this journal aims to disseminate high-quality, peer-reviewed articles that contribute to the understanding, diagnosis, and treatment of these prevalent health issues. Although it operates under a subscription model, it maintains a robust reputation for being a pivotal resource in respiratory health, attracting authors and researchers worldwide. The journal emphasizes interdisciplinary approaches and encourages submissions that span from molecular biology to public health perspectives, making it a vital platform for professionals, researchers, and students eager to deepen their knowledge in respiratory medicine. With a commitment to fostering academic discourse in South Korea and beyond, Allergy Asthma & Respiratory Disease is positioned as a significant contributor to the global conversation on respiratory health.

The Revue Francaise d'Allergologie, an esteemed publication in the field of Immunology and Allergy, is published by ELSEVIER MASSON, CORP OFF in France. This journal plays a pivotal role in disseminating significant findings and advancements in allergy research and immunotherapy, reflecting the latest trends and challenges in these rapidly evolving areas. As part of its commitment to scholarly rigor, the journal encompasses a wide range of topics pertinent to allergology, aiming to bridge the gap between clinical practice and academic research. Although currently not listed as open access, it provides critical insights essential for researchers, professionals, and students alike, ensuring the advancement of knowledge and therapeutic strategies in allergy and immunology. With its impact factor and positioning in the Q4 category, it serves as a valuable resource, aiding in the education and development of future leaders in the field. The Revue Francaise d'Allergologie continues to be a vital platform for the exchange of innovative ideas and findings from 2009 to the present.

Welcome to the Egyptian Journal of Pediatric Allergy and Immunology, a leading academic platform dedicated to the advancement of knowledge in the field of pediatric allergy and immunology. Published by the prestigious Egyptian Society of Pediatric Allergy & Immunology, this journal aims to address the pressing challenges and breakthroughs in the diagnosis, treatment, and management of allergic diseases in children. As a crucial resource for researchers, healthcare professionals, and students, it focuses on disseminating high-quality, peer-reviewed articles that contribute to the global understanding of allergic conditions and immunological responses in pediatric populations. Although the journal is currently not an Open Access publication, it provides a valuable gateway to research findings that can shape clinical practice and influence future investigations. With an emphasis on contributing to improved healthcare outcomes for children suffering from allergy and immunology disorders, the Egyptian Journal of Pediatric Allergy and Immunology stands out as an essential reference in the field.

ALLERGOLOGIE is a prominent academic journal dedicated to the field of immunology and allergy, published by DUSTRI-VERLAG DR KARL FEISTLE in Germany. Since its inception in 1978, the journal has provided a vital platform for researchers, clinicians, and students to disseminate their findings, share insights, and foster advancements in the understanding of allergic diseases and immunological responses. With an ISSN of 0344-5062 and an E-ISSN of the same number, it is a respected source within its category, currently ranked in the 2023 Q4 of the Scopus metrics in immunology and allergy, reflecting its commitment to quality and scholarly rigor. Although not fully open access, ALLERGOLOGIE makes significant contributions to the dialogue on allergy-related topics, encouraging engagement from its readership through a diverse array of articles that span from clinical trials to innovative research methods. This journal continues to be an essential resource for anyone involved in the pursuit of knowledge in allergy and immunology.

Alergia Astma Immunologia is a dedicated journal focusing on the interdisciplinary fields of immunology and respiratory medicine, published by the Asthma and Allergy Patients Support Organization in Poland. With a commitment to advancing research and sharing knowledge, this journal serves as a platform for scholars and practitioners to discuss critical issues and recent advances in allergy, asthma, and immunological disorders. Despite being in Category Quartiles Q4 for both Immunology and Allergy and Pulmonary and Respiratory Medicine, its importance is highlighted by its continuous publication since 2000, providing a historical perspective on evolving scientific insights. Researchers and clinicians alike benefit from accessing novel findings and case studies that contribute to improved patient outcomes and innovative therapeutic strategies. While the journal currently offers limited open access, its commitment to providing high-quality, peer-reviewed content ensures its relevance in the academic discourse within these vital areas of health science. The journal aims to foster collaboration, stimulate research interest, and promote evidence-based practices within the professional community.

ALLERGY is a leading international journal published by WILEY, dedicated to advancing the understanding of allergic diseases and immunology. With an ISSN of 0105-4538 and an E-ISSN of 1398-9995, this esteemed journal has been at the forefront of the field since its inception in 1948 and continues to publish high-quality research up until 2024. Positioned in the Q1 category for both Immunology and Allergy, ALLERGY ranks impressively within the top percentiles of its categories, underscoring its significant impact, as reflected in its Scopus rankings (#11 out of 233 in Immunology and Allergy, and #14 out of 236 in Immunology and Microbiology). Researchers and practitioners accessing this journal can expect a rigorous selection of peer-reviewed articles that address current challenges, innovative therapies, and advancements in the immunological sciences. Although it is not an open-access journal, ALLERGY remains vital for academics, healthcare professionals, and students alike, fostering a deeper understanding of the mechanisms and treatments associated with allergies.

Alergologia Polska - Polish Journal of Allergology, published by TERMEDIA PUBLISHING HOUSE LTD, is a distinguished academic journal dedicated to advancing the field of allergy research and treatment. With the ISSN 2353-3854, this journal serves as an essential resource for professionals, researchers, and students alike, offering a platform for the dissemination of novel findings and comprehensive reviews in allergic diseases. The journal emphasizes open access to ensure widespread availability and engagement within the scientific community. Alergologia Polska aims to enhance the understanding of allergy mechanisms, diagnostics, and management strategies, fostering collaboration and innovation among experts in the field. Set against the vibrant backdrop of Poznań, Poland, this publication not only highlights clinical and experimental research but also promotes interdisciplinary discussions that are pivotal for tackling complex allergic conditions globally.

IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA is a premier journal published by W B SAUNDERS CO-ELSEVIER INC, focusing on the dynamic fields of immunology and allergy. With an ISSN of 0889-8561 and an E-ISSN of 1557-8607, this journal has consistently ranked in the Q2 category in both Immunology and Immunology and Allergy as per 2023 metrics, underscoring its critical role in academia. It provides cutting-edge research, comprehensive reviews, and practical insights that cater to the needs of researchers, clinicians, and students alike. Though the journal is not open access, it remains an essential resource for those involved in advancing knowledge and clinical practice in allergy and immunology. With its converged years stretching from 1987 to 2024, the journal serves as a rich repository of scientific advancements, fostering progress in diagnosis, treatment, and prevention of allergic diseases and immune disorders. Positioned within the United States and based in Philadelphia, it plays a vital role in promoting scholarly communication within these impactful fields.